iNCAS
A crucial point in the drug development cycle is to establish safe, yet effective dosing regimes for initial clinical studies. Many pre-clinical information sources must be analysed to assess safety and appropriate dosage before a decision can be reached.
Working closely with the GSK global safety board, Mango developed an application that allows all relevant information to be stored centrally and presented in a unified manner. This allows project teams to base these vital decisions on all the information at hand (such as pre-clinical data, predicted human exposures, receptor binding characteristics and relevant toxicology findings) using a single, easy to use graphical interface.
The application, iNCAS, allows users to view and interact with the graphical displays, to perform predictive modelling and facilitate sound decision making regarding ongoing safety and dosage regimes.
"Safety is paramount in clinical drug development. However, predicting drug safety is not only a matter of novel techniques, it is also a matter of insight. An accurate evaluation of drug safety depends upon the availability of tools like iNCAS which enables the review of findings across non-clinical species and the integration of such results with pharmacokinetic and pharmacodynamic data in humans. Furthermore, as novel compounds are developed, it is essential to identify the potential for class effects as early as possible. iNCAS brings the safety review process to the 21st Century."
Oscar della Pasqua, Director, CPMS, GlaxoSmithKline
